● neutral
Impact
PhaseApproved/Marketed
Time to marketAlready launched and marketed in Europe (Spain, Portugal, Austria) since 2023-2024.
AdTab lotilaner Updated Nov 9
What to watch
AdTab is a minor regional brand extension of Elanco's lotilaner (Credelio) franchise, launched in select European markets. It faces heavy competition from established flea/tick brands (Bravecto, NexGard, Simparica) and Elanco's own Credelio line. No upcoming binary catalysts exist for this specific product; watch Elanco's broader pet health portfolio (Credelio Quattro, Zenrelia) for material drivers.
Bull case
- Lotilaner is a proven, effective active ingredient with FDA approval in the US under the Credelio brand and a strong safety profile.
- Elanco's broader pet health portfolio is growing: Q3 2026 revenue rose 11% YoY to $1.265B, and the company raised its full-year 2026 outlook.
- Analyst consensus is bullish: 19 of 22 analysts rate ELAN Buy or Strong Buy, with a mean price target of $30.69 (19% upside from $25.74).
Bear case
- AdTab is a minor regional brand confined to a few European markets, competing against well-established flea/tick brands like Bravecto (Merck), NexGard (Boehringer), and Simparica (Zoetis), as well as Elanco's own Credelio.
- Elanco faces a consumer price-fixing class action lawsuit over its flea and tick product market practices, which introduces legal overhang.
- Elanco carries significant debt; the company sold $295M in future lotilaner royalty rights in 2025 to accelerate debt repayment, signaling cash needs.